NASDAQ:PGNX - Progenics Pharmaceuticals Stock Price, Price Target & More

$7.00 -0.02 (-0.28 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$7.00
Today's Range$6.95 - $7.10
52-Week Range$4.60 - $8.63
Volume516,810 shs
Average Volume1.22 million shs
Market Capitalization$510.09 million
P/E Ratio-7.78
Dividend YieldN/A
Beta2.46

About Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals logoProgenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.

Receive PGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:PGNX
CUSIP74318710
Phone646-975-2500

Debt

Debt-to-Equity Ratio0.74%
Current Ratio6.31%
Quick Ratio6.31%

Price-To-Earnings

Trailing P/E Ratio-7.78
Forward P/E Ratio-8.75
P/E GrowthN/A

Sales & Book Value

Annual Sales$11.70 million
Price / Sales43.47
Cash FlowN/A
Price / CashN/A
Book Value$0.90 per share
Price / Book7.78

Profitability

EPS (Most Recent Fiscal Year)($0.90)
Net Income$-51,010,000.00
Net Margins-436.08%
Return on Equity-87.30%
Return on Assets-38.46%

Miscellaneous

Employees64
Outstanding Shares72,660,000

How to Become a New Pot Stock Millionaire

Progenics Pharmaceuticals (NASDAQ:PGNX) Frequently Asked Questions

What is Progenics Pharmaceuticals' stock symbol?

Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."

How were Progenics Pharmaceuticals' earnings last quarter?

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) posted its quarterly earnings results on Thursday, March, 8th. The biotechnology company reported ($0.21) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.21). The biotechnology company had revenue of $3.90 million for the quarter, compared to analysts' expectations of $3.18 million. Progenics Pharmaceuticals had a negative return on equity of 87.30% and a negative net margin of 436.08%. The business's quarterly revenue was down 15.2% on a year-over-year basis. During the same period last year, the firm earned ($0.10) earnings per share. View Progenics Pharmaceuticals' Earnings History.

When is Progenics Pharmaceuticals' next earnings date?

Progenics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for Progenics Pharmaceuticals.

What price target have analysts set for PGNX?

4 analysts have issued 12-month target prices for Progenics Pharmaceuticals' stock. Their forecasts range from $12.00 to $15.00. On average, they expect Progenics Pharmaceuticals' stock price to reach $13.75 in the next year. View Analyst Ratings for Progenics Pharmaceuticals.

What are Wall Street analysts saying about Progenics Pharmaceuticals stock?

Here are some recent quotes from research analysts about Progenics Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. " (4/7/2018)
  • 2. Cantor Fitzgerald analysts commented, "PGNX has completed the rolling NDA for AZEDRA for pheochromocytoma and paraganglioma." (11/2/2017)

Who are some of Progenics Pharmaceuticals' key competitors?

Who are Progenics Pharmaceuticals' key executives?

Progenics Pharmaceuticals' management team includes the folowing people:
  • Peter J. Crowley, Independent Chairman of the Board (Age 59)
  • Mark R. Baker J.D., , Chief Executive Officer, Director (Age 62)
  • Patrick Fabbio, Chief Financial Officer, Senior Vice President (Age 49)
  • Vivien Wong Ph.D., Executive Vice President - Development (Age 60)
  • Jeffrey D. Summer, Senior Vice President - Strategy and Performance (Age 57)
  • Bryce Tenbarge, Vice President - Commercial (Age 44)
  • Bradley L. Campbell, Independent Director (Age 41)
  • Karen Jean Ferrante M.D., Independent Director (Age 59)
  • Michael D. Kishbauch, Independent Director (Age 68)
  • David A. Scheinberg MD., Ph.D., Independent Director (Age 61)

Has Progenics Pharmaceuticals been receiving favorable news coverage?

News stories about PGNX stock have been trending positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Progenics Pharmaceuticals earned a media sentiment score of 0.29 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 46.59 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Progenics Pharmaceuticals?

Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Progenics Pharmaceuticals' stock price today?

One share of PGNX stock can currently be purchased for approximately $7.00.

How big of a company is Progenics Pharmaceuticals?

Progenics Pharmaceuticals has a market capitalization of $510.09 million and generates $11.70 million in revenue each year. The biotechnology company earns $-51,010,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Progenics Pharmaceuticals employs 64 workers across the globe.

How can I contact Progenics Pharmaceuticals?

Progenics Pharmaceuticals' mailing address is 285 FULTON STREET 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]


MarketBeat Community Rating for Progenics Pharmaceuticals (PGNX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  230 (Vote Outperform)
Underperform Votes:  176 (Vote Underperform)
Total Votes:  406
MarketBeat's community ratings are surveys of what our community members think about Progenics Pharmaceuticals and other stocks. Vote "Outperform" if you believe PGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Progenics Pharmaceuticals (NASDAQ:PGNX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Progenics Pharmaceuticals in the last 12 months. Their average twelve-month price target is $13.75, suggesting that the stock has a possible upside of 96.43%. The high price target for PGNX is $15.00 and the low price target for PGNX is $12.00. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.253.253.253.20
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $13.75$13.75$13.75$13.20
Price Target Upside: 96.43% upside64.47% upside123.58% upside86.44% upside

Progenics Pharmaceuticals (NASDAQ:PGNX) Consensus Price Target History

Price Target History for Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals (NASDAQ:PGNX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2018Cantor FitzgeraldSet Price TargetBuy$15.00HighView Rating Details
9/1/2017Needham & Company LLCReiterated RatingStrong-Buy$14.00MediumView Rating Details
8/22/2017AegisReiterated RatingBuy$14.00LowView Rating Details
6/8/2017Jefferies GroupReiterated RatingBuy$12.00HighView Rating Details
11/30/2016BTIG ResearchBoost Price TargetBuy$9.00 -> $11.00N/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$11.00N/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Progenics Pharmaceuticals (NASDAQ:PGNX) Earnings History and Estimates Chart

Earnings by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals (NASDAQ:PGNX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.83)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.23)($0.23)($0.23)
Q2 20181($0.24)($0.24)($0.24)
Q3 20181($0.24)($0.24)($0.24)
Q4 20181($0.12)($0.12)($0.12)

Progenics Pharmaceuticals (NASDAQ PGNX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018($0.19)N/AView Earnings Details
3/8/2018Q4 2017($0.21)($0.21)$3.18 million$3.90 millionViewN/AView Earnings Details
11/2/2017Q3 2017($0.24)($0.22)$3.58 million$2.70 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.20)($0.24)$3.34 million$2.77 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.16)($0.23)$4.50 million$2.40 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.20)($0.10)$4.43 million$4.65 millionViewListenView Earnings Details
11/7/2016Q316$0.55$0.52$52.90 million$53.90 millionViewListenView Earnings Details
8/4/2016Q216($0.13)($0.08)$6.33 million$8.50 millionViewN/AView Earnings Details
5/5/2016Q116($0.13)($0.18)$3.27 million$2.50 millionViewListenView Earnings Details
3/11/2016Q415($0.14)($0.10)$2.25 million$5.10 millionViewListenView Earnings Details
11/9/2015Q315($0.13)($0.14)$2.35 million$1.40 millionViewListenView Earnings Details
8/6/2015Q215($0.15)($0.17)$1.63 million$1.90 millionViewListenView Earnings Details
5/6/2015Q115($0.16)($0.15)$1.30 million$0.25 millionViewN/AView Earnings Details
3/16/2015Q414($0.13)($0.18)$2.87 million($0.57) millionViewN/AView Earnings Details
11/7/2014Q314($0.16)$0.51$2.50 million$41.66 millionViewN/AView Earnings Details
8/8/2014Q214($0.14)($0.17)$2.83 million$1.50 millionViewListenView Earnings Details
5/9/2014Q114($0.15)($0.15)$2.88 million$1.80 millionViewN/AView Earnings Details
3/13/2014Q4($0.19)($0.14)$1.48 million$3.00 millionViewListenView Earnings Details
3/3/2014Q4 2013($0.19)($0.14)$1.74 million$2.97 millionViewN/AView Earnings Details
11/11/2013Q313($0.22)($0.17)$2.00 million$0.90 millionViewN/AView Earnings Details
8/9/2013Q2 2013($0.24)($0.24)$1.86 million$1.80 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.19)($0.22)$1.71 million$2.23 millionViewN/AView Earnings Details
3/15/2013Q4 2012($0.31)($0.01)$1.16 million$8.87 millionViewN/AView Earnings Details
11/8/2012Q312($0.30)($0.33)$2.52 million$1.10 millionViewN/AView Earnings Details
8/9/2012($0.32)($0.32)ViewN/AView Earnings Details
5/8/2012($0.33)($0.39)ViewN/AView Earnings Details
3/15/2012Q4 2011($0.25)($0.32)ViewN/AView Earnings Details
11/9/2011($0.33)($0.34)ViewN/AView Earnings Details
8/9/2011($0.25)$1.64ViewN/AView Earnings Details
5/10/2011($0.51)($0.69)ViewN/AView Earnings Details
3/15/2011($0.57)($0.57)ViewN/AView Earnings Details
11/8/2010Q3 2010($0.56)($0.52)ViewN/AView Earnings Details
8/9/2010Q2 2010($0.54)($0.47)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.41)($0.58)ViewN/AView Earnings Details
3/15/2010Q4 2009($0.14)($0.02)ViewN/AView Earnings Details
11/9/2009Q3 2009($0.44)($0.41)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.50)($0.50)ViewN/AView Earnings Details
5/11/2009Q1 2009($0.27)($0.06)ViewN/AView Earnings Details
3/13/2009Q4 2008($0.30)($0.49)ViewN/AView Earnings Details
11/10/2008Q3 2008($0.28)($0.41)ViewN/AView Earnings Details
8/8/2008Q2 2008$0.01($0.08)ViewN/AView Earnings Details
5/9/2008Q1 2008($0.41)($0.52)ViewN/AView Earnings Details
3/17/2008Q4 2007($0.46)($0.53)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Progenics Pharmaceuticals (NASDAQ:PGNX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Progenics Pharmaceuticals (NASDAQ PGNX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.63%
Institutional Ownership Percentage: 83.75%
Insider Trading History for Progenics Pharmaceuticals (NASDAQ:PGNX)
Insider Trading History for Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals (NASDAQ PGNX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2017Healthcare Master Fun BroadfinMajor ShareholderSell602,600$9.66$5,821,116.00View SEC Filing  
2/9/2017Healthcare Master Fun BroadfinMajor ShareholderSell351,300$9.71$3,411,123.00View SEC Filing  
6/11/2015Robert J IsraelEVPSell2,000$6.83$13,660.00View SEC Filing  
3/13/2015Robert J IsraelEVPSell3,000$7.00$21,000.00View SEC Filing  
3/11/2015Robert J IsraelEVPSell2,000$6.83$13,660.00View SEC Filing  
3/3/2015Robert J IsraelEVPSell5,000$6.49$32,450.00View SEC Filing  
1/12/2015Robert J IsraelEVPSell2,000$7.06$14,120.00View SEC Filing  
12/11/2014Robert J IsraelEVPSell3,000$7.07$21,210.00View SEC Filing  
11/21/2014Robert J IsraelEVPSell9,000$7.00$63,000.00View SEC Filing  
11/13/2014Robert J IsraelEVPSell10,000$6.83$68,300.00View SEC Filing  
11/11/2014Robert J IsraelEVPSell5,000$6.53$32,650.00View SEC Filing  
7/21/2014Healthcare Master Fun BroadfinMajor ShareholderBuy1,625,436$4.60$7,477,005.60View SEC Filing  
7/18/2014Healthcare Master Fun BroadfinMajor ShareholderBuy388,200$4.73$1,836,186.00View SEC Filing  
7/17/2014Healthcare Master Fun BroadfinMajor ShareholderBuy436,884$4.48$1,957,240.32View SEC Filing  
7/16/2014Healthcare Master Fun BroadfinMajor ShareholderBuy411,693$4.48$1,844,384.64View SEC Filing  
7/18/2013Robert J IsraelVPSell5,000$6.33$31,650.00View SEC Filing  
2/27/2013Mark Robert BakerCEOBuy1,262$2.72$3,432.64View SEC Filing  
1/22/2013Mark Robert BakerCEOBuy1,215$2.82$3,426.30View SEC Filing  
12/26/2012Mark Robert BakerCEOBuy1,142$3.01$3,437.42View SEC Filing  
11/28/2012Mark Robert BakerCEOBuy1,607$2.13$3,422.91View SEC Filing  
11/19/2012Mark Robert BakerCEOBuy11,800$1.96$23,128.00View SEC Filing  
11/16/2012Mark Robert BakerCEOBuy49,793$1.82$90,623.26View SEC Filing  
11/15/2012Mark Robert BakerCEOBuy48,833$1.69$82,527.77View SEC Filing  
10/24/2012Mark Robert BakerCEOBuy1,162$2.96$3,439.52View SEC Filing  
9/26/2012Mark Robert BakerCEOBuy1,036$3.32$3,439.52View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Progenics Pharmaceuticals (NASDAQ PGNX) News Headlines

Source:
DateHeadline
Progenics Pharmaceuticals (PGNX) Downgraded by BidaskClubProgenics Pharmaceuticals (PGNX) Downgraded by BidaskClub
www.americanbankingnews.com - April 21 at 7:24 AM
Progenics Pharmaceuticals (PGNX) Stock Rating Lowered by BidaskClubProgenics Pharmaceuticals (PGNX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 19 at 12:49 PM
Progenics Pharmaceuticals, Inc. (PGNX) Receives Consensus Recommendation of "Buy" from BrokeragesProgenics Pharmaceuticals, Inc. (PGNX) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 19 at 5:56 AM
Cantor Fitzgerald Begins Coverage on Progenics Pharmaceuticals (PGNX)Cantor Fitzgerald Begins Coverage on Progenics Pharmaceuticals (PGNX)
www.americanbankingnews.com - April 18 at 8:34 PM
Progenics Pharmaceuticals (PGNX) PT Set at $15.00 by Cantor FitzgeraldProgenics Pharmaceuticals (PGNX) PT Set at $15.00 by Cantor Fitzgerald
www.americanbankingnews.com - April 11 at 7:19 PM
Progenics Talks Commercialization, Pipeline, And MilestonesProgenics Talks Commercialization, Pipeline, And Milestones
seekingalpha.com - April 10 at 9:29 AM
Progenics Pharmaceuticals (PGNX) Buy Rating Reaffirmed at AegisProgenics Pharmaceuticals' (PGNX) Buy Rating Reaffirmed at Aegis
www.americanbankingnews.com - April 9 at 10:55 PM
Progenics Pharmaceuticals (PGNX) Downgraded by Zacks Investment Research to "Sell"Progenics Pharmaceuticals (PGNX) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - April 7 at 7:02 AM
Progenics Pharmaceuticals (PGNX) Downgraded by Zacks Investment ResearchProgenics Pharmaceuticals (PGNX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 6 at 6:29 PM
Equities Analysts Set Expectations for Progenics Pharmaceuticals, Inc.s FY2018 Earnings (PGNX)Equities Analysts Set Expectations for Progenics Pharmaceuticals, Inc.'s FY2018 Earnings (PGNX)
www.americanbankingnews.com - April 6 at 7:24 AM
Progenics Pharmaceuticals (PGNX) Downgraded to "Sell" at Zacks Investment ResearchProgenics Pharmaceuticals (PGNX) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 1 at 11:52 AM
Progenics Pharmaceuticals (PGNX) Given a $15.00 Price Target at Cantor FitzgeraldProgenics Pharmaceuticals (PGNX) Given a $15.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - March 31 at 10:54 AM
Progenics Pharmaceuticals (PGNX) Lifted to Buy at Zacks Investment ResearchProgenics Pharmaceuticals (PGNX) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - March 30 at 6:15 PM
Progenics Pharmaceuticals (PGNX) Downgraded to "Sell" at ValuEngineProgenics Pharmaceuticals (PGNX) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - March 28 at 12:24 PM
Progenics Pharmaceuticals, Inc. (PGNX) Receives Average Rating of "Buy" from BrokeragesProgenics Pharmaceuticals, Inc. (PGNX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 25 at 5:32 AM
3 Things In Biotech, March 23: Booking 3 Pieces Of Bad News3 Things In Biotech, March 23: Booking 3 Pieces Of Bad News
seekingalpha.com - March 24 at 5:12 PM
Progenics Pharmaceuticals (PGNX) Rating Increased to Buy at BidaskClubProgenics Pharmaceuticals (PGNX) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - March 24 at 3:52 PM
Is the FDA Expecting More Problems for Progenics? - 24/7 Wall St.Is the FDA Expecting More Problems for Progenics? - 24/7 Wall St.
247wallst.com - March 24 at 8:19 AM
Progenics Pharmaceuticals Inc (NASDAQ:PGNX) Is Expected To BreakevenProgenics Pharmaceuticals Inc (NASDAQ:PGNX) Is Expected To Breakeven
finance.yahoo.com - March 23 at 9:03 AM
Progenics Pharma (PGNX) Announces Three-Month Extension of PDUFA Date for AZEDRA - StreetInsider.comProgenics Pharma (PGNX) Announces Three-Month Extension of PDUFA Date for AZEDRA - StreetInsider.com
www.streetinsider.com - March 22 at 4:53 PM
Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for AZEDRA® (iobenguane I 131) - GlobeNewswire (press release)Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for AZEDRA® (iobenguane I 131) - GlobeNewswire (press release)
globenewswire.com - March 22 at 4:53 PM
Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for AZEDRA® (iobenguane I 131)Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for AZEDRA® (iobenguane I 131)
finance.yahoo.com - March 22 at 4:53 PM
5 Big Biotech Stocks to Buy Under $10 - Investorplace.com5 Big Biotech Stocks to Buy Under $10 - Investorplace.com
investorplace.com - March 20 at 4:49 PM
Progenics Pharmaceuticals Announces Presentation of AZEDRA ... - NasdaqProgenics Pharmaceuticals Announces Presentation of AZEDRA ... - Nasdaq
www.nasdaq.com - March 20 at 4:49 PM
Progenics Pharmaceuticals, Upcoming PDUFA Date, Analysts Target Price, Pipeline ReviewProgenics Pharmaceuticals, Upcoming PDUFA Date, Analysts Target Price, Pipeline Review
finance.yahoo.com - March 20 at 9:14 AM
Progenics Pharmaceuticals to Present at the 17th Annual Needham Healthcare ConferenceProgenics Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 20 at 9:14 AM
Our Post-Earnings Take On Progenics Pharmaceuticals - Seeking AlphaOur Post-Earnings Take On Progenics Pharmaceuticals - Seeking Alpha
seekingalpha.com - March 13 at 4:59 PM
Progenics Pharmaceuticals, Inc. (PGNX) to Post Q1 2018 Earnings of ($0.23) Per Share, Jefferies Group ForecastsProgenics Pharmaceuticals, Inc. (PGNX) to Post Q1 2018 Earnings of ($0.23) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - March 12 at 1:52 AM
Progenics Pharmaceuticals (PGNX) Upgraded at BidaskClubProgenics Pharmaceuticals (PGNX) Upgraded at BidaskClub
www.americanbankingnews.com - March 10 at 11:34 PM
Progenics Pharmaceuticals (PGNX) Posts Quarterly  Earnings Results, Beats Expectations By $0.19 EPSProgenics Pharmaceuticals (PGNX) Posts Quarterly Earnings Results, Beats Expectations By $0.19 EPS
www.americanbankingnews.com - March 8 at 2:45 PM
Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2017 Financial Results and Business UpdateProgenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2017 Financial Results and Business Update
finance.yahoo.com - March 8 at 10:31 AM
Progenics Pharmaceuticals reports Q4 resultsProgenics Pharmaceuticals reports Q4 results
seekingalpha.com - March 8 at 8:15 AM
Progenics Pharmaceuticals Inc (NASDAQ:PGNX) Is Trading At A 41.88% Discount To Its Intrinsic ValueProgenics Pharmaceuticals Inc (NASDAQ:PGNX) Is Trading At A 41.88% Discount To Its Intrinsic Value
finance.yahoo.com - March 5 at 4:49 PM
Investors Purchase Large Volume of Put Options on Progenics Pharmaceuticals (PGNX)Investors Purchase Large Volume of Put Options on Progenics Pharmaceuticals (PGNX)
www.americanbankingnews.com - March 2 at 7:30 AM
Traders Buy High Volume of Call Options on Progenics Pharmaceuticals (PGNX)Traders Buy High Volume of Call Options on Progenics Pharmaceuticals (PGNX)
www.americanbankingnews.com - March 2 at 7:28 AM
Fuller & Thaler Asset Management Inc. Sells 106,400 Shares of Progenics Pharmaceuticals, Inc. (PGNX)Fuller & Thaler Asset Management Inc. Sells 106,400 Shares of Progenics Pharmaceuticals, Inc. (PGNX)
www.americanbankingnews.com - March 1 at 10:50 AM
Progenics Pharmaceuticals Sets Fourth Quarter and Year-End 2017 Financial Results Call for March 8Progenics Pharmaceuticals Sets Fourth Quarter and Year-End 2017 Financial Results Call for March 8
finance.yahoo.com - March 1 at 9:25 AM
Carillon Tower Advisers Inc. Invests $21.79 Million in Progenics Pharmaceuticals, Inc. (PGNX)Carillon Tower Advisers Inc. Invests $21.79 Million in Progenics Pharmaceuticals, Inc. (PGNX)
www.americanbankingnews.com - March 1 at 5:38 AM
Progenics Pharmaceuticals, Inc. (PGNX) Shares Sold by Royce & Associates LPProgenics Pharmaceuticals, Inc. (PGNX) Shares Sold by Royce & Associates LP
www.americanbankingnews.com - February 28 at 9:42 AM
Progenics Pharmaceuticals (PGNX) Set to Announce Quarterly Earnings on WednesdayProgenics Pharmaceuticals (PGNX) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 28 at 1:40 AM
KBC Group NV Has $1.30 Million Stake in Progenics Pharmaceuticals, Inc. (PGNX)KBC Group NV Has $1.30 Million Stake in Progenics Pharmaceuticals, Inc. (PGNX)
www.americanbankingnews.com - February 25 at 6:40 AM
Progenics Pharmaceuticals (PGNX) Presents At RBC Capital Markets Global Healthcare Conference - SlideshowProgenics Pharmaceuticals (PGNX) Presents At RBC Capital Markets Global Healthcare Conference - Slideshow
seekingalpha.com - February 23 at 4:42 PM
Progenics Pharmaceuticals (PGNX) Lifted to Hold at BidaskClubProgenics Pharmaceuticals (PGNX) Lifted to Hold at BidaskClub
www.americanbankingnews.com - February 18 at 1:00 PM
Progenics Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare ConferenceProgenics Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - February 15 at 4:46 PM
Progenics Pharmaceuticals Sees Unusually High Options Volume (PGNX)Progenics Pharmaceuticals Sees Unusually High Options Volume (PGNX)
www.americanbankingnews.com - February 14 at 5:50 PM
Progenics Pharmaceuticals (PGNX) Presents At BIO CEO & Investor Conference - SlideshowProgenics Pharmaceuticals (PGNX) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 14 at 3:27 PM
Progenics Pharmaceuticals to Present at the 2018 BIO CEO & Investor ConferenceProgenics Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference
finance.yahoo.com - February 5 at 3:24 PM
Progenics Pharmaceuticals, Inc. (PGNX) Given Consensus Recommendation of "Hold" by BrokeragesProgenics Pharmaceuticals, Inc. (PGNX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 3 at 5:28 AM
Progenics Pharma (PGNX) Announces Presentation of AZEDRA Biochemical Tumor Marker Data at ENDO - StreetInsider.comProgenics Pharma (PGNX) Announces Presentation of AZEDRA Biochemical Tumor Marker Data at ENDO - StreetInsider.com
www.streetinsider.com - February 2 at 6:28 AM
Progenics Pharmaceuticals Announces Presentation of AZEDRA® (iobenguane I 131) Biochemical Tumor Marker Data at the 2018 Endocrine Society (ENDO) Annual MeetingProgenics Pharmaceuticals Announces Presentation of AZEDRA® (iobenguane I 131) Biochemical Tumor Marker Data at the 2018 Endocrine Society (ENDO) Annual Meeting
feeds.benzinga.com - February 1 at 5:13 PM

SEC Filings

Progenics Pharmaceuticals (NASDAQ:PGNX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Progenics Pharmaceuticals (NASDAQ:PGNX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Progenics Pharmaceuticals (NASDAQ PGNX) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.